Review
doi: 10.1016/j.pedn.2010.06.011.
Epub 2010 Aug 19.
A community health concern: respiratory syncytial virus and children
Affiliations
- PMID: 21035019
- DOI: 10.1016/j.pedn.2010.06.011
Item in Clipboard
Review
A community health concern: respiratory syncytial virus and children
J Pediatr Nurs.
2010 Dec.
Abstract
Respiratory syncytial virus (RSV) is a significant health issue. Nearly all children contract RSV by 3 years of age. This virus causes mild cold-like symptoms in older children and adults. However, in infants and toddlers, it causes serious lower respiratory tract infections. Recovery from RSV can be lengthy, and caring for an unwell child can become a burden for a family. Prevention plans for those children that are at highest risk have been helpful in reducing the incidence of RSV. The American Academy of Pediatrics outlines the use of Palivizumab as part of its RSV prevention guidelines.
Copyright © 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.Pediatrics. 1998 Sep;102(3 Pt 1):531-7. Pediatrics. 1998. PMID: 9738173 Clinical Trial.
-
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.Pediatrics. 2003 Dec;112(6 Pt 1):1442-6. Pediatrics. 2003. PMID: 14654627
-
Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.Arch Pediatr Adolesc Med. 2011 Jun;165(6):498-505. doi: 10.1001/archpediatrics.2010.298. Epub 2011 Feb 7. Arch Pediatr Adolesc Med. 2011. PMID: 21300647
-
[Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].Klin Padiatr. 1999 Nov-Dec;211(6):450-5. doi: 10.1055/s-2008-1043832. Klin Padiatr. 1999. PMID: 10592925 Review. German.
-
Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?Clin Ther. 2004 Dec;26(12):2130-7. doi: 10.1016/j.clinthera.2004.12.005. Clin Ther. 2004. PMID: 15823776 Review.
Cited by
-
Communicable diseases prioritized for surveillance and epidemiological research: results of a standardized prioritization procedure in Germany, 2011.PLoS One. 2011;6(10):e25691. doi: 10.1371/journal.pone.0025691. Epub 2011 Oct 4. PLoS One. 2011. PMID: 21991334 Free PMC article.
-
Comparison of direct fluorescence assay and real-time rt-PCR as diagnostics for respiratory syncytial virus in young children.J Trop Med. 2011;2011:781919. doi: 10.1155/2011/781919. Epub 2011 Dec 14. J Trop Med. 2011. PMID: 22220181 Free PMC article.
-
Impact of genetic polymorphisms related to innate immune response on respiratory syncytial virus infection in children.Virus Genes. 2022 Dec;58(6):501-514. doi: 10.1007/s11262-022-01932-6. Epub 2022 Sep 9. Virus Genes. 2022. PMID: 36085536 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
